NCT06108414View on ClinicalTrials.gov

Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

PHASE4RecruitingINTERVENTIONAL
Enrollment

4,374

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Atrial FibrillationAnticoagulant Adverse ReactionStrokeMajor Adverse Cardiac Events
Interventions
DRUG

low-dose rivaroxaban

Rivaroxaban 15mg q.d. (The dose should be reduced to 10mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)

DRUG

Standard-dose rivaroxaban

Rivaroxaban 20mg q.d. (The dose should be reduced to 15mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)

Trial Locations (1)

100037

RECRUITING

National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

China National Center for Cardiovascular Diseases

OTHER_GOV